Celldex returned to XVIVO to create a medical animation explaining the mechanism behind barzolvolimab, a monoclonal antibody that targets mast cells. After first working together in 2011, collaborating again with Celldex founder and CSO, Dr. Tibor Keler, made this project both meaningful and a reminder of why we love telling science stories.
The animation visualizes how barzolvolimab blocks KIT receptors on mast cells. By preventing KIT dimerization and downstream signaling, barzolvolimab can deplete mast cells, which could be a therapeutic option for conditions driven by chronic mast cell activation. Our focus was on clear scientific communication, showing the process in a way that helps viewers understand the underlying biology.
From the overview of healthy mast cell function, to chronic activation, the animation concentrates the complexities of immune cell function and disease into more intuitive and accessible content. . Every decision was guided by accuracy and clarity. The result is a piece of medical education that makes complex immunology approachable, supporting researchers and clinicians as they communicate their science to broader audiences.
Premiering at the 2025 EAACI Congress, the animation now lives on Celldex’s website, helping share the science behind barzolvolimab with a broader audience. We’re proud to have supported Celldex once again to make their science seen, understood, and remembered.
Related Animations
